ADReCS

Pharmaceutical Information

Drug Name	Imatinib
Drug ID	BADD_D01136
Description	Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage	For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status	approved
ATC Code	L01EA01
DrugBank ID	DB00619
KEGG ID	D08066
MeSH ID	D000068877
PubChem ID	5291
TTD Drug ID	D0AZ3C
NDC Product Code	63850-4826; 68554-0034; 43598-345; 65162-795; 42292-044; 0378-2246; 43598-344; 51407-270; 0378-2245; 42292-043; 51407-269; 48087-0143; 65162-794
UNII	BKJ8M8G5HI
Synonyms	Imatinib Mesylate \| Mesylate, Imatinib \| Imatinib Methanesulfonate \| Methanesulfonate, Imatinib \| STI571 \| STI-571 \| STI 571 \| Gleevec \| Glivec \| ST 1571 \| ST1571 \| CGP 57148 \| CGP57148B \| CGP-57148 \| CGP57148 \| Imatinib \| Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide

Chemical Information

Molecular Formula	C29H31N7O
CAS Registry Number	152459-95-5
SMILES	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Acute graft versus host disease	12.02.09.002; 10.02.01.028	0.000336%		Not Available
Chronic graft versus host disease	12.02.09.003; 10.02.01.029	0.000336%		Not Available
Cytopenia	01.03.03.012	0.000783%		Not Available
Thyroid cancer	16.24.03.001; 05.02.05.001	0.000280%		Not Available
Haematological malignancy	16.21.01.002; 01.13.01.003	0.000168%		Not Available
Treatment failure	08.06.01.017	0.007398%		Not Available
Liver injury	12.01.17.012; 09.01.07.022	0.000504%		Not Available
Low birth weight baby	18.04.02.003	0.001007%		Not Available
Oral disorder	07.05.01.005	0.000112%		Not Available
Gastrointestinal sounds abnormal	07.01.01.002	-	-	Not Available
Mucosal pigmentation	08.01.06.006	0.000112%		Not Available
Focal segmental glomerulosclerosis	20.05.01.003	0.000112%		Not Available
Skin mass	23.07.04.014	0.001019%		Not Available
Renal cell carcinoma	16.08.02.002; 20.01.04.003	0.000280%		Not Available
Oropharyngeal discomfort	22.12.03.015; 07.05.05.008	-	-	Not Available
Oropharyngeal pain	22.12.03.016; 07.05.05.004	-	-
Epstein-Barr virus associated lymphoproliferative disorder	16.21.02.002; 11.05.10.001; 01.13.02.002	0.000392%		Not Available
Acute kidney injury	20.01.03.016	-	-
Bone marrow reticulin fibrosis	16.32.03.010; 01.05.01.009	0.000280%		Not Available
Foetal growth restriction	18.03.01.002	0.000336%
Skin sensitisation	23.03.03.052; 10.02.01.038	0.000112%		Not Available
Gastrointestinal tract irritation	07.08.03.008	0.000817%		Not Available
Intraductal proliferative breast lesion	21.05.01.014; 16.10.01.006	0.000168%		Not Available
Platelet dysfunction	01.08.03.003	0.000783%		Not Available
Drug reaction with eosinophilia and systemic symptoms	12.03.01.064; 23.03.05.005; 10.01.01.021	0.000951%		Not Available
Autoimmune haemolytic anaemia	10.04.01.005; 01.06.01.004	0.000224%		Not Available
Faeces soft	07.01.03.008	0.000246%		Not Available
Mouth swelling	23.04.01.020; 10.01.05.020; 07.05.04.007	0.000246%		Not Available
Multiple organ dysfunction syndrome	08.01.03.057	0.001343%
Myeloproliferative neoplasm	16.21.03.006; 01.13.03.006	0.000280%		Not Available

The 27th Page First Pre 27 28 29 30 31 Next Last Total 32 Pages